News Bell: Penumbra, Inc. (NYSE:PEN) & Adaptimmune Therapeutics plc (NASDAQ:ADAP)

3

Penumbra, Inc. (NYSE:PEN)

Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company’s portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California.

Penumbra, Inc. (NYSE:PEN)’s Financial Overview

Penumbra, Inc. (NYSE) surged 1.55% yesterday to close its trading session at $153.18. The company has 1 year Price Target of $160.14. Penumbra, Inc. has 52-Week high of $167.35 and 52-Week Low of $90.05. The stock touched its 52-Week High on 167.35 and 52-Week Low on 88.80. The stock traded with the volume of 208617 shares yesterday. The firm shows the market capitalization of $5.31 Billion.

Penumbra, Inc. (NYSE) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $0.17/share against the analyst consensus estimate of $0.04/share. The difference between the actual and expected EPS is $0.13 a share with a surprise factor of 325%.

The firm is trading with SMA20 of 7.87 Percent, SMA50 of 15.4 Percent and SMA200 of 9.35 percent. Penumbra, Inc. has P/S value of 12.64 while its P/B value stands at 12.82. Similarly, the company has Return on Assets of 1.8 percent, Return on Equity of 2.2 percent and Return on Investment of 5.6 Percent. The company shows Gross Margin and Operating Margin of 66.1 percent and -0.9 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 0 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 7 analysts offering 12-month price forecasts for Penumbra Inc have a median target of 160.00, with a high estimate of 180.00 and a low estimate of 140.00. The median estimate represents a +4.45% increase from the last price of 153.18.

Penumbra, Inc. is expected* to report earnings on 02/26/2019 after market close. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.11. The reported EPS for the same quarter last year was $0.1.

Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.

Adaptimmune Therapeutics plc (NASDAQ:ADAP)’s Financial Outlook

The 7 analysts offering 12-month price forecasts for Adaptimmune Therapeutics PLC have a median target of 16.00, with a high estimate of 18.00 and a low estimate of 7.00. The median estimate represents a +200.19% increase from the last price of 5.33.

Adaptimmune Therapeutics plc is expected* to report earnings on 02/27/2019 before market open. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 6 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.33. The reported EPS for the same quarter last year was $-0.29.

According to Zacks Investment Research, Adaptimmune Therapeutics plc has a Consensus Recommendation of 2. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock surged 3.5% and closed its last trading session at $5.33. The company has the market capitalization of $519.41 Million. The stock has 52-week high of $14.62 and 52-Week low of $3.6. The firm touched its 52-Week high on 14.63 and 52-Week low on 3.60. The company has volume of 214754 shares. The company has a total of 97.45 Million shares outstanding.

Adaptimmune Therapeutics plc (NASDAQ) in the last quarter reported its actual EPS of $0.06/share where the analyst estimated EPS was $-0.06/share. The difference between the actual and Estimated EPS is $0.12. This shows a surprise factor of 200 percent.

The company has YTD performance of -7.3 percent. Beta for Adaptimmune Therapeutics plc stands at 1.36 while its ATR (average true range) is 0.37. The company has Weekly Volatility of 7.28%% and Monthly Volatility of 7.65%%.

Adaptimmune Therapeutics plc has distance from 20-day Simple Moving Average (SMA20) of 9.93%, Distance from 50-Day Simple Moving Average of 3.96 percent and Distance from 200-Day Simple Moving Average of -42.54%.

The Company currently has ROA (Return on Assets) of -33 percent, Return on Equity (ROE) of -41.5 Percent and Return on Investment (ROI) of -40% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.

SHARE